'Wave of innovation': Why ASX 200 healthcare shares are poised for new growth

After struggling in 2023, Janus Henderson Investors says the healthcare sector's long-term outlook appears stronger than ever.

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index (ASX: XJO) healthcare shares have broadly underperformed the benchmark over the past year.

Over the last 12 months the ASX 200 has gained 6%. As for the big healthcare stocks, the S&P/ASX 200 Health Care Index (ASX: XHJ) has gone the other way, shedding 10%.

Looking at some of the leading healthcare stocks, biotechnology company CSL Ltd (ASX: CSL) shares are down 14% over that time. While sleep technology company ResMed Inc (ASX: RMD) has seen its share price tumble by 35%.

Of course, not all ASX 200 healthcare shares have lost ground. Cochlear implant device manufacturer Cochlear Ltd (ASX: COH), for example, has enjoyed a 32% increase in its share price over 12 months.

Still, with the broader healthcare sector in retreat over the past year, the outlook for 2024 is looking bright, according to Janus Henderson Investors.

Strong outlook for ASX 200 healthcare shares

Despite the lagging performance in 2023, Janus Henderson Investors portfolio managers Andy Acker and Dan Lyons say the sector's long-term outlook "appears stronger than ever".

"We think this is an attractive time to be investing in the healthcare sector," Acker said.

He noted that "it's usually after a period of underperformance that investors get less interested".

However, Acker believes that's a common mistake, saying that instead, this is "exactly when we think an investor should be more interested".

Despite signs emerging of a potential 'soft landing' for the economy, Janus Henderson believes we could still be in for "a substantial slowing of the economy and a potential recession, especially as we get into 2024".

This could benefit ASX 200 healthcare shares, as Acker believes this is when "the defensive characteristics of the healthcare sector really rise to the fore and become more appreciated".

According to Acker:

At the same time, the valuations in the sector are at significant discounts to the overall market, whereas historically, they trade at premiums because of their durable nature of growth in the sector.

And long-term investors in ASX 200 healthcare shares could benefit from the innovation sweeping the sector.

Acker added:

You have this wave of innovation where we're seeing this revolution in biology that's driving so many new products. This year we think will be a record year for new products; as many as 80 could be coming to the market.

And this is driving a whole new product cycle in healthcare that we think could drive growth, not just for the next few years, but for the next decade or more.

ASX 200 healthcare shares, and smaller ASX healthcare stocks, could also be set to benefit from a sharp uptick in mergers and acquisitions (M&A).

"I've seen estimates of around $600 billion of cash that's out there available for potential spending on M&A," Lyons said. "And we think that's going to be an important driver of interest in the sector, as well."

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »